Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy.

When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab / G. Damiani, R.R.Z. Conic, V. de Vita, A. Costanzo, R. Regazzini, P.D.M. Pigatto, N.L. Bragazzi, A. Pacifico, P. Malagoli. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2018 Dec 05). [Epub ahead of print] [10.1111/dth.12793]

When IL-17 inhibitors fail : real-life evidence to switch from secukinumab to adalimumab or ustekinumab

G. Damiani
;
P.D.M. Pigatto
Conceptualization
;
2018-12-05

Abstract

Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy.
DLQI; PASI; adalimumab; psoriasis; real-life; secukinumab; switching; ustekinumab
Settore MED/35 - Malattie Cutanee e Veneree
5-dic-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
When IL 17 inhibitors.pdf

embargo fino al 05/02/2020

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.72 MB
Formato Adobe PDF
2.72 MB Adobe PDF Visualizza/Apri
Damiani_et_al-2018-Dermatologic_Therapy.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 802.42 kB
Formato Adobe PDF
802.42 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/605533
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 28
social impact